marimastat has been researched along with Pancreatic Neoplasms in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Du, Y; Pang, Y; Tang, J; Wang, R; Xie, J; Zhang, Q; Zhao, J; Zhou, X | 1 |
| Haage, A; Schneider, IC | 1 |
| Bloomston, M; Rosemurgy, AS; Zervos, EE | 1 |
| Heinemann, V | 1 |
| Abbruzzese, JL; McConkey, D; Pino, SM; Xiong, HQ | 1 |
| McCann, PP; Rasmussen, HS | 1 |
| Bramhall, SR | 1 |
| Casper, E; Goode, S; Harris, J; Langleben, A; Rasmussen, H; Rosemurgy, A | 1 |
| Abbruzzese, JL; Hess, KR | 1 |
| Bowry, C; Bramhall, SR; Brown, PD; Buckels, JA; Rosemurgy, A | 1 |
| Brown, P; Buckels, J; Carmichael, J; Daniel, F; Evans, JD; Imrie, CW; Johnson, CD; Neoptolemos, JP; Stark, A | 1 |
| Wolff, RA | 1 |
| Baillet, M; Bramhall, SR; Brown, PD; Buckels, JA; Nemunaitis, J; Schulz, J | 1 |
6 review(s) available for marimastat and Pancreatic Neoplasms
| Article | Year |
|---|---|
Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.
Topics: Animals; Antineoplastic Agents; Gene Expression Regulation, Enzymologic; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Pancreatic Neoplasms; Tissue Inhibitor of Metalloproteinases; Transfection | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Novel therapies for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cysteine Endopeptidases; Deoxycytidine; Epidermal Growth Factor; Gemcitabine; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Multienzyme Complexes; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; RNA, Antisense | 2004 |
Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Enzyme Inhibitors; Female; Hemangioma; Humans; Hydroxamic Acids; Melanoma; Metalloendopeptidases; Mice; Ovarian Neoplasms; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Skin Neoplasms; Thiophenes | 1997 |
Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition.
Topics: Animals; Cell Adhesion Molecules; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxamic Acids; Metalloendopeptidases; Pancreatic Neoplasms; Tissue Inhibitor of Metalloproteinases | 1998 |
Exploiting molecular targets in pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Cycle Proteins; Cetuximab; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins p21(ras); Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Research Design; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab; Tumor Suppressor Protein p53 | 2002 |
4 trial(s) available for marimastat and Pancreatic Neoplasms
| Article | Year |
|---|---|
Marimastat in patients with advanced pancreatic cancer: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Agents; CA-19-9 Antigen; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Male; Metalloendopeptidases; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 1999 |
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Humans; Hydroxamic Acids; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2001 |
A phase II trial of marimastat in advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-19-9 Antigen; Female; Gastrointestinal Diseases; Humans; Hydroxamic Acids; Life Tables; Male; Metalloendopeptidases; Middle Aged; Musculoskeletal Diseases; Neoplasm Proteins; Neoplasm Staging; Pain; Palliative Care; Pancreatic Neoplasms; Pilot Projects; Protease Inhibitors; Quality of Life; Survival Analysis; Treatment Outcome | 2001 |
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Hydroxamic Acids; Life Tables; Male; Matrix Metalloproteinase Inhibitors; Middle Aged; Musculoskeletal Diseases; Neoplasm Proteins; Pancreatic Neoplasms; Protease Inhibitors; Quality of Life; Safety; Survival Analysis | 2002 |
4 other study(ies) available for marimastat and Pancreatic Neoplasms
| Article | Year |
|---|---|
Identification of potential diagnostic biomarkers in MMPs for pancreatic carcinoma.
Topics: Biomarkers; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Metalloendopeptidases; Pancreatic Neoplasms; Prognosis | 2021 |
Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Shape; Collagen; Elasticity; Extracellular Matrix; Gels; Heparan Sulfate Proteoglycans; Heparin Lyase; Humans; Hydroxamic Acids; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Proteins; Pancreatic Neoplasms; Recombinant Proteins | 2014 |
Marimastat. BB 2516, TA 2516.
Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Drugs, Investigational; Female; Humans; Hydroxamic Acids; Male; Melanoma; Metalloendopeptidases; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Stomach Neoplasms | 1999 |
Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design.
Topics: Enzyme Inhibitors; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2001 |